資訊|論壇|病例

搜索

首頁(yè) 醫(yī)學(xué)論壇 專業(yè)文章 醫(yī)學(xué)進(jìn)展 簽約作者 病例中心 快問診所 愛醫(yī)培訓(xùn) 醫(yī)學(xué)考試 在線題庫(kù) 醫(yī)學(xué)會(huì)議

您所在的位置:首頁(yè) > 肝病科診療指南 > 2004GPAC慢性乙型肝炎的臨床管理

2004GPAC慢性乙型肝炎的臨床管理

2013-09-03 10:21 閱讀:1214 來源:愛愛醫(yī)資源網(wǎng) 責(zé)任編輯:愛愛醫(yī)資源
[導(dǎo)讀] 《2004GPAC慢性乙型肝炎的臨床管理》內(nèi)容預(yù)覽 Treatment should be given by a physician with expertise in hepatitis. Notes: As ALT, serology and nucleic acid tests are imperfect markers, a liver biopsy is strongly indicated before treatment is

《2004GPAC慢性乙型肝炎的臨床管理》內(nèi)容預(yù)覽

Treatment should be given by a physician with expertise in hepatitis.
Notes: As ALT, serology and nucleic acid tests are imperfect markers, a liver biopsy is strongly indicated before treatment is initiated.
Treatment with interferon for 16 weeks will lead to an antiviral response in 25 to 30 per cent of individuals. Treatment with lamivudine for a year or more will lead to an antiviral response in 15 to 40 per cent of individuals. Prolonged therapy increases the risk of antiviral resistance.
What constitutes a hepatitis B antiviral response is complicated because of viral variability in patients and variability in the interpretation of the different available tests, e.g. ALT, HBsAg, HBeAg, HBV DNA. Treatment protocols for chronic hepatitis B are constantly evolving. A recent document on the management of viral hepatitis is available at:http://www.hepatology.ca/cm/FileLib/ViralHepatitisCanadianConsensus2004.pdf

點(diǎn)擊下載完整版:《2004GPAC慢性乙型肝炎的臨床管理》


分享到:
  版權(quán)聲明:

  本站所注明來源為"愛愛醫(yī)"的文章,版權(quán)歸作者與本站共同所有,非經(jīng)授權(quán)不得轉(zhuǎn)載。

  本站所有轉(zhuǎn)載文章系出于傳遞更多信息之目的,且明確注明來源和作者,不希望被轉(zhuǎn)載的媒體或個(gè)人可與我們

  聯(lián)系z(mì)lzs@120.net,我們將立即進(jìn)行刪除處理

意見反饋 關(guān)于我們 隱私保護(hù) 版權(quán)聲明 友情鏈接 聯(lián)系我們

Copyright 2002-2024 Iiyi.Com All Rights Reserved